Vitruvian Partners LLP Buys Shares of 144,300 RxSight, Inc. (NASDAQ:RXST)

Vitruvian Partners LLP acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 144,300 shares of the company's stock, valued at approximately $4,961,000. RxSight comprises about 4.3% of Vitruvian Partners LLP's portfolio, making the stock its 5th largest holding. Vitruvian Partners LLP owned about 0.36% of RxSight at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of RXST. Quarry LP increased its position in shares of RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company's stock worth $32,000 after acquiring an additional 288 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in RxSight in the 3rd quarter worth approximately $34,000. Private Trust Co. NA purchased a new position in RxSight during the 4th quarter worth approximately $34,000. Arcadia Investment Management Corp MI acquired a new stake in RxSight during the 4th quarter valued at $46,000. Finally, Harbor Investment Advisory LLC purchased a new stake in shares of RxSight in the fourth quarter valued at $52,000. Institutional investors and hedge funds own 78.78% of the company's stock.

RxSight Price Performance

RXST traded up $2.30 during midday trading on Thursday, hitting $26.67. 860,634 shares of the company's stock traded hands, compared to its average volume of 533,346. The company has a market cap of $1.08 billion, a PE ratio of -32.13 and a beta of 1.22. The stock's fifty day simple moving average is $29.18 and its 200-day simple moving average is $39.35. RxSight, Inc. has a one year low of $24.09 and a one year high of $66.54.

Remove Ads

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The business had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. On average, research analysts expect that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Buying and Selling at RxSight

In related news, Director Jesse Anderson Corley purchased 1,443 shares of the stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the acquisition, the director now directly owns 1,443 shares in the company, valued at approximately $44,992.74. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company's stock, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on RxSight from $62.00 to $40.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. UBS Group initiated coverage on RxSight in a research report on Friday, December 6th. They set a "buy" rating and a $52.00 price objective for the company. Bank of America dropped their target price on RxSight from $60.00 to $36.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Wells Fargo & Company decreased their price target on shares of RxSight from $40.00 to $35.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $43.00 price objective on shares of RxSight in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $49.33.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.